Cortical Stimulation for Tinnitus Cortical and Deep Brain Stimulation for Depression and Obsessive Compulsive Disorder Intraoperative Image-Guidance for Deep Brain Stimulation
Electrophysiological Biomarkers to Optimize Deep Brain Stimulation for Depression
The Icahn School of Medicine at Mount Sinai is running a single-center experimental trial of deep brain stimulation (DBS) to the subcallosal cingulate region (Area 25) for treatment resistant depression (TRD). The goal of this study is to refine and optimize this treatment approach using a newly available neuromodulation system (the Medtronic Summit RC+S) that allows brain activity during ongoing therapeutic DBS to be recorded from the brain in real-time. This study will further define brain readouts that track depression recovery, providing novel strategies to monitor and guide treatment and device programming decisions in patients receiving DBS for TRD.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Kopell during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Abbott Neuromodulation
Turing Medical
Medtronic, Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Kopell during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Abbott Neuromodulation
Turing Medical
Medtronic, Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.